Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Active, not recruiting · NCT05145062 · Registry updated 2025-11-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, lymphatic system disorder, sickle cell disease, thalassemia | Active, not recruiting | Not stated | 2025-11-12 | NCT05145062 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sangamo Therapeutics | 5 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital | Boston | United States | 343 |
| Children's Healthcare of Atlanta | Atlanta | United States | 38 |
| Henry Ford Health System | Detroit | United States | 147 |
| Karmanos Cancer Institute | Detroit | United States | 153 |
| UCSF Benioff Children's Hospital | Oakland | United States | 10 |
| University of California Davis Health System | Sacramento | United States | 10 |
| University of Minnesota | Minneapolis | United States | 325 |